Laura Lee Sandler filed a Form 3 initial statement of beneficial ownership with the SEC on November 12, 2026, reporting her status as a newly appointed director of InMed Pharmaceuticals Inc. as of November 6, 2026.

Key Highlights

  • Reporting person: Laura Lee Sandler, identified as a Director of InMed Pharmaceuticals Inc.
  • Event date: The date of the event requiring the statement is listed as November 6, 2026.
  • Filing date: The form was signed and filed on November 12, 2026, by Jerad G. Seurer as attorney-in-fact for Laura Sandler.
  • No securities held: The filing states, "No securities are beneficially owned," with both Table I (non-derivative securities) and Table II (derivative securities) left blank.
  • Issuer and ticker: The issuer is identified as InMed Pharmaceuticals Inc., listed on NASDAQ:MTRI.

InMed Pharmaceuticals Director Sandler Reports Zero Beneficial Ownership at Appointment

According to the filing, Laura Lee Sandler submitted a Form 3 initial statement of beneficial ownership in connection with her role as a Director at InMed Pharmaceuticals Inc. (NASDAQ:MTRI). The event triggering the filing is dated November 6, 2026, and the form was filed on November 12, 2026. The registrant's address is listed as 221 Crescent St., Building 23, Suite 105, Waltham, Massachusetts 02453.

The filing discloses that Sandler does not beneficially own any securities of the issuer. Both Table I, covering non-derivative securities such as common stock, and Table II, covering derivative securities such as options or warrants, contain no entries. The filing explicitly states, "No securities are beneficially owned." This Form 3 represents only an initial disclosure of ownership status and does not reflect any acquisition or disposition of shares.

The form was signed by Jerad G. Seurer as attorney-in-fact for Laura Sandler, with an attached Exhibit 24 - Power of Attorney referenced in the filing. The relationship box checked on the form identifies Sandler solely as a Director, with no officer title or 10% owner designation indicated.

What Was Disclosed

InMed Pharmaceuticals director Laura Lee Sandler filed an initial beneficial ownership statement reporting zero securities held, either directly or indirectly, in non-derivative or derivative form, as of the November 6, 2026 event date.